BMO Lifts IAMGOLD Price Target To US$3.25 Following Board Rework

On February 14th, BMO Capital Markets upgraded IAMGOLD Corporation (TSX: IMG) from market perform to outperform and raised their 12-month price target on the stock to US$3.25 from US$2.75. This follows the firm completing negotiations with an activist investor. With this, IAMGOLD is expected to replace 5 of its 9 directors by the May 2022 annual general meeting. This comes after IAMGOLD publicly rejected the shareholders demands.

They believe that the renewed board of directors will “flow-through” the line management. They upgraded IAMGOLD “on expectations of improved execution and strategic vision for the company going forward.”

IAMGOLD currently has 10 analysts covering the stock with an average 12-month price target of C$3.87, or a 2% upside to the current stock price. Out of the 10 analysts, 3 have buy ratings, 6 have hold ratings and a single analyst has a sell rating on the stock. The street high sits at C$5.50 from TD and represents a 45% upside to the stock price.

BMO calls these corporate changes a “promising pivot” as they believe that this conclusion shows that IAMGOLD is coming into the discussions with a positive and open mind. They expect that the renewed board will help put a fresh set of eyes on the management at the company.

They expect that the first thing the board will do is appoint a permanent CEO. The next item they are hoping the board will do is appoint a known “turnaround” expert, who has experience with Canadian mining operations. They believe that this will help boost confidence and allow the current interim CFO, Daniella Dimitrov, to focus on optimizing the balance sheet.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

Cineplex: Canaccord Lifts Price Target To $18 On Improving Outlook

On May 13, Cineplex Inc. (TSX: CGX) reported its first quarter financial results. The company...

Friday, May 20, 2022, 04:07:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM

Valens: Analysts Reiterate Price Targets, Ratings Following Q3 Results

Last week, The Valens Company (TSX: VLNS) reported their third-quarter results. Revenues were stable quarter...

Tuesday, October 20, 2020, 12:19:00 PM

Raymond James: Villages Farms Worth Upwards Of $27 Following Full Pure Sunfarms Ownership

Today, analyst Rahul Sarugaser from Raymond James sent out a note to investors about Village...

Tuesday, August 25, 2020, 04:25:08 PM

Paradigm Initiates Coverage On Trulieve With $59 Price Target

Earlier this month, Paradigm Capital initiated coverage on Trulieve Cannabis Corp (CSE: TRUL) with a...

Sunday, December 27, 2020, 01:42:00 PM